These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16289766)

  • 1. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
    Schulze K; Medina E; Guzmán CA
    Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI.
    Guzmán CA; Talay SR; Molinari G; Medina E; Chhatwal GS
    J Infect Dis; 1999 Apr; 179(4):901-6. PubMed ID: 10068585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.
    Schulze K; Olive C; Ebensen T; Guzmán CA
    Vaccine; 2006 Aug; 24(35-36):6088-95. PubMed ID: 16828529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
    Mannam P; Jones KF; Geller BL
    Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
    Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
    J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model.
    McArthur J; Medina E; Mueller A; Chin J; Currie BJ; Sriprakash KS; Talay SR; Chhatwal GS; Walker MJ
    Infect Immun; 2004 Dec; 72(12):7342-5. PubMed ID: 15557665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opacity factor activity and epithelial cell binding by the serum opacity factor protein of Streptococcus pyogenes are functionally discrete.
    Gillen CM; Courtney HS; Schulze K; Rohde M; Wilson MR; Timmer AM; Guzman CA; Nizet V; Chhatwal GS; Walker MJ
    J Biol Chem; 2008 Mar; 283(10):6359-66. PubMed ID: 18180300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the SfbI protein.
    Schulze K; Medina E; Chhatwal GS; Guzmán CA
    Vaccine; 2003 May; 21(17-18):1958-64. PubMed ID: 12706684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the domain of fibronectin-binding protein I of Streptococcus pyogenes responsible for elicitation of a protective immune response.
    Schulze K; Medina E; Talay SR; Towers RJ; Chhatwal GS; Guzmán CA
    Infect Immun; 2001 Jan; 69(1):622-5. PubMed ID: 11119566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
    Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
    Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice.
    Okamoto S; Tamura Y; Terao Y; Hamada S; Kawabata S
    Vaccine; 2005 Sep; 23(40):4852-9. PubMed ID: 15990202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice.
    Xue G; Yu L; Li S; Shen X
    FEMS Immunol Med Microbiol; 2010 Mar; 58(2):202-10. PubMed ID: 19912341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective immunity against Streptococcus pyogenes challenge in mice after immunization with fibronectin-binding protein.
    Terao Y; Okamoto S; Kataoka K; Hamada S; Kawabata S
    J Infect Dis; 2005 Dec; 192(12):2081-91. PubMed ID: 16288371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
    Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
    J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal and systemic immunization with targeted fusion anti-caries DNA plasmid in young rats.
    Liu GX; Xu QA; Jin J; Li YH; Jia R; Guo JH; Fan MW
    Vaccine; 2009 May; 27(22):2940-7. PubMed ID: 19428904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenic characterization and protection against Streptococcus mutans infection induced by intranasal DNA prime-protein boost immunization.
    Li YH; Huang S; Du M; Bian Z; Chen Z; Fan MW
    Vaccine; 2010 Jul; 28(32):5370-6. PubMed ID: 20573581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.
    Mortensen R; Christensen D; Hansen LB; Christensen JP; Andersen P; Dietrich J
    PLoS One; 2017; 12(4):e0175707. PubMed ID: 28414746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.
    Batzloff MR; Yan H; Davies MR; Hartas J; Lowell GH; White G; Burt DS; Leanderson T; Good MF
    J Infect Dis; 2005 Oct; 192(8):1450-5. PubMed ID: 16170764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.